Natco Pharma Ltd, founded in 1981, has established itself as one of India’s premier pharmaceutical companies. Headquartered in Hyderabad, the company specializes in developing, manufacturing, and marketing finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs).
Known for its strategic focus on complex generics and niche therapeutic areas, Natco has built a strong reputation in oncology, hepatitis C, and central nervous system medications. The company’s business model prioritizes challenging the patents of major pharmaceutical corporations through Paragraph IV filings in the United States, giving it a competitive edge in launching affordable generic alternatives.
Natco’s international footprint spans key markets including the United States, Europe, Brazil, and Canada, with a growing presence in emerging economies. The company operates state-of-the-art manufacturing facilities that meet global regulatory standards, including USFDA and EU GMP certifications.
Beyond its commercial success, Natco has demonstrated social responsibility through its affordable medicine initiatives, particularly during public health crises. The company gained significant recognition during the hepatitis C epidemic by providing cost-effective alternatives to expensive branded treatments.
Under the leadership of its founder and chairman V.C. Nannapaneni, Natco continues to balance profitability with its mission of making life-saving medications accessible to patients worldwide, positioning itself as a significant player in the global pharmaceutical landscape.
Natco Pharma Ltd is listed on both major Indian stock exchanges: the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE). The company’s shares trade under the ticker symbol “NATCOPHARM” on the NSE and “524816” on the BSE. These listings make Natco’s shares available to both Indian and international investors interested in the Indian pharmaceutical sector.
Exchanges:
NSE – National Stock Exchange of India
BSE – Bombay Stock Exchange
newshub
Recent Comments